Phillip Md Et Al Frost Gamm... Net Worth

The estimated Net Worth of Phillip Md Et Al Frost Gamm... is at least $591 million dollars as of 23 May 2024. Phillip Gamm owns over 100,000 units of BioCardia stock worth over $574,551,644 and over the last 17 years Phillip sold BCDA stock worth over $16,393,664.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Phillip Gamm BCDA stock SEC Form 4 insiders trading

Phillip has made over 1517 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently Phillip bought 100,000 units of BCDA stock worth $127,000 on 23 May 2024.

The largest trade Phillip's ever made was selling 19,230,769 units of BioCardia stock on 21 December 2016 worth over $2,500,000. On average, Phillip trades about 95,431 units every 4 days since 2007. As of 23 May 2024 Phillip still owns at least 211,232,222 units of BioCardia stock.

You can see the complete history of Phillip Gamm stock trades at the bottom of the page.

What's Phillip Gamm's mailing address?

Phillip's mailing address filed with the SEC is 4400 BISCAYNE BLVD4400 BISCAYNE BLVD, , MIAMIMIAMI, FLFL, 3313733137.

Insiders trading at BioCardia

Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer et Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.

What does BioCardia do?

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Complete history of Phillip Gamm stock trades at Opko Health Inc, Northrop Grumman, Protalix BioTherapeutics, Osaic Services, Cocrystal Pharma Inc, Red Violet Inc, Fluent Inc, Osaic Services et BioCardia